Abstract P6-14-04: Rosehip extracts prevent triple negative breast cancer cell proliferation by regulation the phosphorylation of p70S6 Kinase.

Triple Negative Breast Cancer (TNBC) is an aggressive form of breast cancer, characterized by its lack of the human epidermal growth factor receptor-2 (HER-2), the estrogen receptor (ER), and the progesterone receptor (PR). Due to the lack of these hormone receptors, TNBC has abnormal therapeutic results; leading to the need for unique treatment methods. TNBC has a partial response to chemotherapy, which is associated with the lack of clinically established targeted therapies. Plant extracts have shown to be useful as chemopreventive agents due to their disruption of pro-survival and proliferative mechanisms on cancer cells. Rosehip extracts have shown potential anti-proliferative activity against cancer cells in vitro. This study investigated the effect of rosehip extracts in TNBC cell lines (HCC1806 and MB157) and basal-like breast cancer cell lines (HCC70 and HCC1500). To determine the inhibitory role of rosehip extracts in cell proliferation, MTT assays were conducted, following treatment with varying concentrations of rosehip extracts (1mg/ml, 250ug/ml, 25ug/ml, and 25ng/ml) for 48 hours. The data suggests that rosehip extracts, can significantly decrease cell proliferation in all the breast cancer cell lines assayed. Preliminary studies suggest that this is accomplished without toxic effects. Western blot analysis was used to investigate which signaling pathway rosehip extracts were affecting. Western Blot analysis suggests that rosehip extracts are inhibiting p70 S6 kinase phosphorylation and its ability to act as a kinase for S6 ribosomal protein. Based on these findings, rosehip extracts prevent cell proliferation by interfering with the p70 S6 kinase signaling. Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P6-14-04.